144 related articles for article (PubMed ID: 31679947)
1. Entering the era of highly effective CFTR modulator therapy.
Zemanick ET; Accurso FJ
Lancet; 2019 Nov; 394(10212):1886-1888. PubMed ID: 31679947
[No Abstract] [Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
3. Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation.
McGarry ME
N Engl J Med; 2020 Feb; 382(7):684. PubMed ID: 32053310
[No Abstract] [Full Text] [Related]
4. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
5. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
[TBL] [Abstract][Full Text] [Related]
6. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
7. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
9. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
10. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
[TBL] [Abstract][Full Text] [Related]
11. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
12. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
[TBL] [Abstract][Full Text] [Related]
13. Triple CFTR Modulator Therapy for Cystic Fibrosis.
Holguin F
N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694
[No Abstract] [Full Text] [Related]
14. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
Bulloch MN; Hanna C; Giovane R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
[TBL] [Abstract][Full Text] [Related]
15. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
16. Pulmonology: CFTR modulators for cystic fibrosis.
Bertoncini E; Colomb-Lippa D
JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
[No Abstract] [Full Text] [Related]
17. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Rehman A; Baloch NU; Janahi IA
N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035
[No Abstract] [Full Text] [Related]
18. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE; Elborn JS; Ramsey BW
N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034
[No Abstract] [Full Text] [Related]
19. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
[No Abstract] [Full Text] [Related]
20. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
Zhang S; Shrestha CL; Kopp BT
Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
